!!Daniel Peeper - Biography
\\
Daniel Peeper is the Head of the Department of Molecular Oncology and chairs both the Scientific Faculty Council and the Translational Research Board at the Netherlands Cancer Institute (NKI). He holds a professorship in Functional Oncogenomics at the VU University Medical Center (VUmc). \\
\\
Peeper studied Medical Biology at the VU University and received his PhD in the laboratory of Alex van der Eb at the University of Leiden (1994), for his work on adenoviral oncoproteins and cell cycle proteins. He received his postdoctoral training in the laboratories of Mark Ewen (Dana-Farber Cancer Institute, Harvard Medical School, Boston) and René Bernards (NKI). In 2002, Peeper became Assistant Professor and three years later Associate Professor at NKI. Also in that year, he was elected as an EMBO Young Investigator. \\
\\
In 2002 and 2006, he received NWO VIDI and VICI awards, respectively for his functional oncogenomic studies. In 2007, he received the first KWF Queen Wilhelmina Award, by her Majesty the Queen Beatrix and the minister of Education, for his work on melanoma in collaboration with W. Mooi. In the same year, he received the Society for Melanoma Research Jr. Researcher Award. In 2008, Peeper was appointed affiliate Professor at the VUmc and was elected as EMBO member. In 2013, he received, together with colleagues including A Berns and M Stratton (Sanger Inst.), an ERC Synergy grant (€15 million) for the development of combinatorial cancer therapy. In 2015, he received the Outstanding research award by the Society for Melanoma Research.\\
Peeper is a member of the European Association for Cancer Research (EACR) Board, and he also serves on the EACR Conference committee. \\
\\
Highlights of the Peeper lab include their discoveries that a genomic screen for anoikis resistance can be used to identify metastasis genes (Nature 2004); that Oncogene-Induced cellular Senescence (OIS) serves as a potent in vivo tumor suppressor mechanism limiting cancer progression (Nature 2005; New Engl J Med 2006); the identification of several OIS-associated oncogenes (Nat Cell Biol 2005; Nat Rev Cancer 2006); that OIS is associated with the activation of an inflammatory transcriptome  (Cell 2008;  Nat  Rev  Cancer  2009;  Genes   Dev  2010);  the identification  of  a  novel  candidate  melanoma  suppressor  gene  (EMBO J, 2011) and of a key mechanism of human melanomagenesis involving abrogation of OIS by reduction of PTEN expression (Genes Dev 2012). His laboratory also identified a prognostic breast cancer genetic signature and a factor essential to drive metastasis (PNAS 2013) and discovered that pyruvate dehydrogenase kinase (PDK1) acts as a critical switch for the execution of OIS and serves as an attractive drug target in melanoma (Nature 2013). More recently, Peeper and his team demonstrated the power of in vivo shRNA dropout screens for drug target identification (Cell Rep. 2014) and discovered a new mechanism mediating broad resistance to targeted therapy in melanoma (Nature Commun 2014). Most recently, they identified multiple resistance mechanisms to BRAF targeted therapy in a melanoma patient (EMBO Mol Med 2015) and developed a new bioinformatic tool to determine copy number alterations in cancer (Genome Biol 2015).